Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Metallomics

• Publication date

  2014-11-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c4mt00192cPMID 25387565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy.

  2015cited by this paper
• Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis

  2014cited by this paper
• ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.

  2014cited by this paper
• Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

  2014cited by this paper
• Cisplatin handover between copper transporters: the effect of reducing agents

  2014cited by this paper
• The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis

  2014cited by this paper
• Metallothionein – Immunohistochemical Cancer Biomarker: A Meta-Analysis

  2014cited by this paper
• ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.

  2014cited by this paper
• Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.

  2014cited by this paper
• Pt-based drugs: the spotlight will be on proteins.

  2014cited by this paper
• SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women

  2014cited by this paper
• Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle.

  2014cited by this paper
• Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing

  2014cited by this paper
• Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.

  2014cited by this paper
• Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer

  2014cited by this paper
• Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.

  2014cited by this paper
• A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATP-binding cassette transporter upregulation and high glutathione levels

  2014cited by this paper
• Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

  2014cited by this paper
• The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.

  2014cited by this paper
• ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.

  2014cited by this paper
• Complementarity of MALDI and LA ICP mass spectrometry for platinum anticancer imaging in human tumor.

  2014cited by this paper
• Determining the effect of DNA methylation on gene expression in cancer cells.

  2014cited by this paper
• Misinterpretation of TPMT by a DTC Genetic Testing Company

  2014cited by this paper
• MALDI mass spectrometry in prostate cancer biomarker discovery.

  2014cited by this paper
• Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair.

  2013cited by this paper
• ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial

  2013cited by this paper
• Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Reverse-Phase Protein Array Analysis to Identify Biomarker Proteins in Human Pancreatic Cancer

  2013cited by this paper
• Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells

  2013cited by this paper
• Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

  2013cited by this paper
• Ovarian Cancer - A Clinical and Translational Update

  2013cited by this paper
• The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin‐Induced Ototoxicity in Children With Cancer

  2013cited by this paper
• OmniSpect: An Open MATLAB-Based Tool for Visualization and Analysis of Matrix-Assisted Laser Desorption/Ionization and Desorption Electrospray Ionization Mass Spectrometry Images

  2013cited by this paper
• Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine

  2013cited by this paper
• Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.

  2013cited by this paper
• Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

  2013cited by this paper
• Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes

  2013cited by this paper
• 2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage.

  2013cited by this paper
• ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.

  2013cited by this paper
• Development of a scalable pharmacogenomic clinical decision support service.

  2013cited by this paper
• KRAS mutations in lung cancer.

  2013cited by this paper
• A multi-parametric microarray for protein profiling: simultaneous analysis of 8 different cytochromes via differentially element tagged antibodies and laser ablation ICP-MS.

  2013cited by this paper
• RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae.

  2012cited by this paper
• Cellular interactions of platinum drugs

  2012cited by this paper
• DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.

  2012cited by this paper
• Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.

  2012cited by this paper
• Clinical Pharmacokinetics and Administration of Established Platinum Drugs

  2012cited by this paper
• A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.

  2012cited by this paper
• RNA Sequencing: Platform Selection, Experimental Design, and Data Interpretation

  2012cited by this paper
• Interactions of oxaliplatin with the cytoplasmic thiol containing ligand glutathione.

  2012cited by this paper
• MiRNA-21

  2012cited by this paper
• Molecular mechanisms of cisplatin resistance

  2012cited by this paper
• Suppression of Jab1/CSN5 induces radiation- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways

  2012cited by this paper
• Determination of Pt–DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry

  2011cited by this paper
• Mitochondrial Liaisons of p53

  2011cited by this paper
• Prognostic significance of differentially expressed miRNAs in esophageal cancer

  2011cited by this paper
• Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons.

  2011cited by this paper
• Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.

  2011cited by this paper
• Autophagy inhibition enhances apoptosis triggered by BO-1051, an N-mustard derivative, and involves the ATM signaling pathway.

  2011cited by this paper
• Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer

  2011cited by this paper
• Speciation of oxaliplatin adducts with DNA nucleotides.

  2011cited by this paper
• Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line

  2010cited by this paper
• Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance

  2010cited by this paper
• Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

  2010cited by this paper
• Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells.

  2010cited by this paper
• Bioinformatics in bioinorganic chemistry.

  2010cited by this paper
• Inhibition of Both Thioredoxin Reductase and Glutathione Reductase may Contribute to the Anticancer Mechanism of TH-302

  2010cited by this paper
• FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells

  2010cited by this paper
• DNA Repair–Based Mechanisms of Platinum Resistance in Epithelial Ovarian Cancer: From Bench to Bedside

  2010cited by this paper
• Platinum drug distribution in cancer cells and tumors.

  2009cited by this paper
• Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin

  2009cited by this paper
• Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

  2009cited by this paper
• MITICS (MALDI Imaging Team Imaging Computing System): a new open source mass spectrometry imaging software.

  2008cited by this paper
• Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver

  2008cited by this paper
• Validation and Quality Control of Protein Microarray-based Analytical Methods

  2008cited by this paper
• Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

  2008cited by this paper
• Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.

  2007cited by this paper
• Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification method

  2007cited by this paper
• A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry

  2007cited by this paper
• Thioredoxin signaling as a target for cancer therapy.

  2007cited by this paper
• Protein microarray technology

  2006cited by this paper
• Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.

  2005cited by this paper
• Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine.

  2004cited by this paper
• Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.

  2003cited by this paper
• Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry.

  2003cited by this paper
• Transition Metal Speciation in the Cell: Insights from the Chemistry of Metal Ion Receptors

  2003cited by this paper
• Human exposure to metals. Pathways of exposure, biomarkers of effect, and host factors.

  2003cited by this paper
• Particular aspects of platinum compounds used at present in cancer treatment.

  2002cited by this paper
• Protein microarray technology.

  2002cited by this paper
• Is cisplatin-induced cell death always produced by apoptosis?

  2001cited by this paper
• Cisplatin: from DNA damage to cancer chemotherapy.

  2001cited by this paper
• Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs.

  2001cited by this paper
• How nucleotide excision repair protects against cancer

  2001cited by this paper
• ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1

  2001cited by this paper
• Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.

  2001cited by this paper
• Post-translational modifications and activation of p53 by genotoxic stresses.

  2001cited by this paper
• Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.

  2000cited by this paper
• The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

  2000cited by this paper

• Coordination compounds in cancer: Past, present and perspectives

  2015cites this paper